At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
|Articles|November 12, 2012
Not Enough Cancer Drugs, Too Many Price Controls
Advertisement
Cancer patients face daunting challenges, including side effects of treatment, impact on family life and work disruptions. They now face another problem: shortages of vital drugs.
Imagine an oncologist talking to his patient: Everything is going well with your treatment, he says, but one of the drugs you've been receiving is unavailable. There's a substitute—sort of. Your Medicare copayment for the drug we've been using is $9. Now it will cost you $520 each time the substitute is given.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
Advertisement
Advertisement
Trending on AJMC
1
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
2
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5